Article
Multidisciplinary Sciences
Johan Fernstrom, Lars Ohlsson, Marie Asp, Eva Lavant, Amanda Holck, Cecile Grudet, Asa Westrin, Daniel Lindqvist
Summary: Plasma ccf-mtDNA levels vary in different subtypes of depression, with treatment with mood stabilizers associated with lower ccf-mtDNA. The findings suggest that ccf-mtDNA regulation may differ in various forms of depression and warrant further investigation.
Article
Oncology
Patricia Mondelo-Macia, Jorge Garcia-Gonzalez, Alicia Abalo, Manuel Mosquera-Presedo, Santiago Aguin, Maria Mateos, Rafael Lopez-Lopez, Luis Leon-Mateos, Laura Muinelo-Romay, Roberto Diaz-Pena
Summary: This study confirmed the prognostic value of cfDNA quantitative analysis in SCLC patients before and during therapy, and developed a new risk prognostic model that can help identify patients who could benefit from current treatments.
TRANSLATIONAL LUNG CANCER RESEARCH
(2022)
Article
Cell Biology
Sara Bonlokke, Magnus Stougaard, Boe Sandahl Sorensen, Berit Bargum Booth, Estrid Hogdall, Gitte-Bettina Nyvang, Jacob Christian Lindegaard, Jan Blaakaer, Jesper Bertelsen, Katrine Fuglsang, Mikael Lenz Strube, Suzan Lenz, Torben Steiniche
Summary: Circulating cell-free HPV DNA (ccfHPV DNA) can serve as a marker for cervical cancer. This study used digital droplet PCR (ddPCR) to detect and quantify ccfHPV DNA in plasma from patients with HPV16- or HPV18-associated cervical cancer. The results showed that ccfHPV DNA may not be useful for early detection of cervical cancer, but it can be a promising tool for establishing tumor burden and monitoring the disease in advanced stage cervical cancer patients.
Article
Genetics & Heredity
Ekaterina Pisareva, Benoit Roch, Cynthia Sanchez, Brice Pastor, Alexia Mirandola, Mona Diab-Assaf, Thibault Mazard, Corinne Prevostel, Zahra Al Amir Dache, Alain R. Thierry
Summary: This study directly compares the structural features of circulating nuclear DNA (cir-nDNA) and circulating mitochondrial DNA (cir-mtDNA), revealing significant differences between them due to the topological structure of chromatin in the nucleus and plasmids in the mitochondria. Despite their association with mono-nucleosomes and cell-free mitochondria, this study highlights the diversity of circulating structures associated with cell-free DNA.
FRONTIERS IN GENETICS
(2023)
Article
Oncology
Geoffroy Poulet, Fanny Garlan, Sonia Garrigou, Eleonora Zonta, Leonor Benhaim, Marie-Jennifer Carrillon, Audrey Didelot, Delphine Le Corre, Claire Mulot, Philippe Nizard, Frederic Ginot, Audrey Boutonnet-Rodat, Helene Blons, Jean-Baptiste Bachet, Julien Taieb, Aziz Zaanan, Vanna Geromel, Laurence Pellegrina, Pierre Laurent-Puig, Shu-Fang Wang-Renault, Valerie Taly
Summary: Research has shown that ccfDNA is highly fragmented in metastatic colorectal cancer patients compared to healthy individuals. These results strongly suggest that characterizing ccfDNA integrity holds great promise for developing a universal biomarker for the follow-up of mCRC patients. Furthermore, the results support the importance of standardizing sample handling and processing in such analysis.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Cloud P. Paweletz, Grace A. Heavey, Yanan Kuang, Emily Durlacher, Thian Kheoh, Richard C. Chao, Alexander I. Spira, Konstantinos Leventakos, Melissa L. Johnson, Sai-Hong Ignatius Ou, Gregory J. Riely, Kenna Anderes, Wenjing Yang, James G. Christensen, Pasi A. Janne
Summary: This study reports on early ctDNA changes of KRAS G12C in lung cancer patients and suggests that ctDNA changes can be used as a potential measure for early prediction of clinical response.
CLINICAL CANCER RESEARCH
(2023)
Review
Oncology
Maria Gabriela O. Fernandes, Natalia Cruz-Martins, Jose Carlos Machado, Jose Luis Costa, Venceslau Hespanhol
Summary: Liquid biopsy, specifically plasma ctDNA analysis, has revolutionized cancer patient management by detecting genomic alterations and resistance mechanisms, particularly in lung cancer patients. While offering a comprehensive view of tumor diversity, its non-invasive nature overcomes the challenges of obtaining tissue samples. Further clarification is needed regarding the use of LB in supporting diagnostic and therapeutic decisions.
CANCER CELL INTERNATIONAL
(2021)
Editorial Material
Medicine, General & Internal
Mary E. Norton
Summary: The 2022 Lasker-DeBakey Clinical Medical Research Award is awarded to Yuk Ming Dennis Lo for his discovery of fetal DNA in the maternal circulation, which has revolutionized prenatal screening.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Woo Kyung Ryu, Sekyung Oh, Jun Hyeok Lim, Seung Jae Lee, Hyun-Tae Shin, Jeong-Seon Ryu
Summary: Recent research suggests that changes in ctDNA levels are correlated with TB changes, and the detection of ctDNA can be used to predict new metastases, rapid tumor growth, and poor survival in NSCLC patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Respiratory System
Wei-Wei Peng, Ying Liu, Huan-Huan Sha, Shao-Di Wen, Ying Fang, Guo-Ren Zhou
Summary: This study investigated the relationship between cfDNA concentration and treatment outcomes in advanced NSCLC patients. Lower cfDNA concentration before treatment and NLR<2.98 were associated with better prognosis. Increased cfDNA concentration before the third treatment was an independent factor for disease progression.
BMC PULMONARY MEDICINE
(2023)
Article
Environmental Sciences
Olga Bulgakova, Assiya Kussainova, Anuarbek Kakabayev, Akmaral Aripova, Gulim Baikenova, Alberto Izzotti, Rakhmetkazhi Bersimbaev
Summary: This study found that the level of cf mtDNA in radon-induced lung cancer patients was significantly higher than other study participants, and there was a significant difference in cf mtDNA levels in the blood plasma of healthy volunteers exposed and not exposed to high doses of radon. Overall, healthy volunteers living in areas with high radon levels had higher mtDNA copy numbers than lung cancer patients who were not exposed to high doses of radon.
ENVIRONMENTAL RESEARCH
(2022)
Article
Multidisciplinary Sciences
Joanna Kapeleris, Juliana MUller Bark, Shanon Ranjit, Darryl Irwin, Gunter Hartel, Majid Ebrahimi Warkiani, Paul Leo, Connor O'Leary, Rahul Ladwa, Kenneth O'Byrne, Brett G. M. Hughes, Chamindie Punyadeera
Summary: This pilot study demonstrated that combining CTC cluster counts and cfDNA levels can predict progression-free survival in NSCLC patients. The results encourage further exploration of the combined effect of CTC/cfDNA as a prognostic biomarker in a large cohort of advanced stage NSCLC patients.
Review
Biology
Nicole Laurencia Yuwono, Kristina Warton, Caroline Elizabeth Ford
Summary: Research and clinical use of circulating cell-free DNA (cirDNA) is expanding rapidly, but gaps remain in understanding the influence of lifestyle and biological factors on cirDNA levels. Despite inconsistencies, acute exercise was identified as a significant influence on cirDNA levels, suggesting the need for controlling physical activity in study design. Proper selection and reporting of laboratory protocols are crucial for improving reproducibility in cirDNA studies.
Article
Biochemistry & Molecular Biology
Xiaojing Chen, Shaojuan Lai, Chuxiong Zhuang, Jilei Huang, Yufei Hu
Summary: The study utilized SC-PCR to detect single-copy T-DNA plants and found that single-copy T-DNA integrations were more frequent in transgenic T-1 Arabidopsis without a vector backbone. By combining negative screening of the vector backbone and SC-PCR, they efficiently identified single-copy T-DNA plants. Additionally, the study highlighted the need to reevaluate PCR-based methods for detecting T-DNA copy number in plants containing inverted T-DNA repeats.
Article
Oncology
Maria Gabriela O. Fernandes, Natalia Cruz-Martins, Conceicao Souto Moura, Susana Guimaraes, Joana Pereira Reis, Ana Justino, Maria Joao Pina, Adriana Magalhaes, Henrique Queiroga, Jose Carlos Machado, Venceslau Hespanhol, Jose Luis Costa
Summary: Plasma ctDNA testing showed high accuracy and clinical relevance in newly diagnosed advanced NSCLC patients, highlighting its potential as a valuable tool for mutation detection in clinical practice.